Award
National Cancer Institute 5R01CA288617-03
TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer
Recipient
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Award Amount
$370,575.00
Ceiling
$370,575.00
Awarded
March 04, 2026
Identifier
5R01CA288617-03
This award funds the development and clinical testing of genetically engineered CAR-NK cells targeting TROP2 for pancreatic cancer treatment, aiming to improve safety and efficacy through advanced genetic modifications and clinical trials.
Description
Development of off-the-shelf GMP-grade CAR-NK cells targeting TROP2 for pancreatic ductal adenocarcinoma, including a Phase I/II clinical trial to evaluate safety and efficacy, and studies on cell fate, tumor microenvironment interactions, and metabolic modulation.